Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?

Theo M. De Witte, David Bowen, Marie Robin, Luca Malcovati, Ghulam Mufti, Dietger Niederwieser, Ibrahim Yakoubagha, Nicolaus Kröger

Research output: Contribution to journalArticlepeer-review

Abstract

The selection of a treatment strategy before allogeneic hematopoietic stem cell transplant (HSCT) for myelodysplastic syndrome is a delicate process. The expected relapse risk and nonrelapse mortality after HSCT and the response rates to the pretransplant strategies all play a role in this process. Fit patients younger than 60 to 65 years with > 10% marrow blasts and without high-risk cytogenetic abnormalities should be seriously considered for intensive chemotherapy (ICT) to reduce tumor load before HSCT. Other patients up to the age of 75 years may be considered for hypomethylating agent therapy before transplant. Patients with high-risk cytogenetic abnormalities should be treated in investigational protocols if they are not candidates for ICT.

Original languageEnglish
Pages (from-to)S42-S45
JournalClinical Lymphoma, Myeloma and Leukemia
Volume14
DOIs
Publication statusPublished - Sep 1 2014

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Cytoreduction with hypomethylating agents
  • Cytoreduction with intensive chemotherapy
  • High-Risk myelodysplastic syndrome
  • Transformed myelodysplastic syndrome

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?'. Together they form a unique fingerprint.

Cite this